DHR vs RVTY: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
DHR is the larger of the two ($157.25B market cap): the incumbent the market prices for continued execution (23.98x forward earnings, beta 0.80). RVTY is the smaller challenger ($16.28B), priced similarly on forward earnings (24.48x): more room to run, but more to prove. If the story you believe is DHR's (Bioprocessing recovery), DHR is the more direct way to own it; if it is RVTY's (Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics), RVTY is.
DHR vs RVTY: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | DHR | RVTY | What it tells you |
|---|---|---|---|
| Market cap | $157.25B | $16.28B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 23.98 | 24.48 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 37.01 | 64.80 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.80 | 1.09 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 76% of range | 71% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.93 | 2.24 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how DHR and RVTY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DHR and RVTY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DHR and RVTY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Danaher Corporation (DHR) do?
Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.
What does Revvity (RVTY) do?
Revvity runs two reporting segments of nearly identical size. Life Sciences sold ~$720.5 million in the first half of fiscal 2026 and covers two product lines: Life Sciences Solutions (~$601.0 million), meaning reagents, assays, labeling and detection chemistry, automation and high-content imaging systems such as the Opera Phenix platform, and Signals software (~$119.5 million), a scientific informatics suite sold on subscription to pharmaceutical R&D organizations. Diagnostics sold ~$720.3 million over the same period and also splits two ways: immunodiagnostics (~$416.6 million), largely the EUROIMMUN autoimmune, allergy and infectious-disease immunoassay franchise, and reproductive health (~$303.7 million), which is newborn screening, prenatal testing and related genomic services. Customers are pharmaceutical and biotech R&D groups, clinical and public-health laboratories, academia and governments across more than 160 countries, served by roughly 11,000 employees. Geography is spread wide rather than concentrated: in the June quarter the Americas produced ~$325.6 million, Europe ~$229.0 million and Asia ~$175.1 million. A large share of revenue is consumable or subscription in nature, since assays, reagents and screening kits get bought again every period, while instruments and software licenses carry the cyclical part of the business.
DHR vs RVTY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.
- RVTY drivers: Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics; The China immunodiagnostics exit resets the base.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 37x on GAAP earnings with a forward P/E near 24x as of November 20, 2026), leaving little room for disappointment. For RVTY, the most immediate risk is that a chunk of 2026 profit does not repeat.
DHR or RVTY: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate DHR from RVTY. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DHR and RVTY guides.
DHR vs RVTY: the full fundamentals
DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, and growth picked up to about 5.5% in the second quarter of 2026 and about 8.3% in the third. The stock trades near 24x forward earnings and about 22x EV/EBITDA as of November 20, 2026, within its usual premium range, with consensus EPS of about $8.59 for 2026 and $9.32 for 2027. The 21 analysts tracked by Yahoo Finance hold a strong buy consensus with a mean target near $260, about 16% above the latest close; figures are approximate.
RVTY. The multiple depends entirely on which earnings line an owner treats as economic. A trailing GAAP P/E near 65x reflects ~$340 million a year of amortization on intangibles Revvity paid cash for in prior years; a multiple near 27x on 2026 consensus adjusted EPS, or about 24x on 2027 consensus, treats that amortization as sunk. After a roughly 48% gain in 2026 the stock carries a premium closer to faster-compounding life-science tools names than to slow-growth diagnostics, while reported revenue grew only about 4.3% in the third quarter. The fourth-quarter report, expected around February 1, 2027, is the next test of whether margin, buybacks and the instrument backlog can carry that premium.
Headline figures (approximate, November 2026): DHR shows revenue (ttm) ~$25.6B; Q3 2026 ~$6.55B (+8.3%), q3 2026 adj. eps $2.11 vs ~$1.92 estimate, margins (ttm) ~59.4% gross, ~22.0% operating, ~16.9% net, net income (ttm) ~$4.29B (GAAP EPS ~$6.04); RVTY shows revenue (ttm) ~$2.94 billion for the twelve months to October 4, 2026, with third-quarter revenue of ~$709.6 million up about 4.3% year over year and above the ~$695 million consensus. Growth has been slow rather than absent: ~$2.751 billion in fiscal 2023, ~$2.755 billion in fiscal 2024 and ~$2.856 billion in fiscal 2025. Analysts expect ~$2.87 billion for fiscal 2026 and ~$3.04 billion for 2027. Note that fiscal 2026 ends January 3, 2027 and contains 53 weeks, one more than fiscal 2025., gaap earnings versus adjusted earnings Trailing twelve-month net income is ~$253 million and trailing diluted EPS ~$2.25, against $2.07 for full-year 2025 and $2.20 for 2024. Adjusted EPS was $1.37 in the September quarter against a $1.30 estimate, after $1.41 against $1.22 in the June quarter and $1.06 against $1.01 in the March quarter. In the June quarter the bridge was $0.76 of intangible amortization, $0.32 of restructuring, $0.05 of investment mark-to-market and $0.02 of purchase accounting, less $0.21 of tax. Consensus adjusted EPS is ~$5.44 for 2026 and ~$5.96 for 2027; in August management had guided 2026 pro forma adjusted EPS to $5.30 to $5.40., margins On Yahoo Finance's trailing basis, gross margin is ~55.9%, GAAP operating margin ~16.7% and net margin ~8.6%. Adjusted operating margin ran 28.9% in the June quarter against a GAAP operating margin of 12.2%, the gap being intangible amortization from past acquisitions., segment and product-line mix First-half 2026 revenue splits almost evenly, Life Sciences ~$720.5 million and Diagnostics ~$720.3 million. Within Life Sciences: Life Sciences Solutions ~$601.0 million and Signals software ~$119.5 million. Within Diagnostics: immunodiagnostics ~$416.6 million and reproductive health ~$303.7 million. Segment adjusted operating margins in the June quarter were 31.1% for Life Sciences (down from 31.6%) and 30.4% for Diagnostics (up from 25.2%)..
The bottom line: DHR vs RVTY
DHR and RVTY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined DHR and RVTY exposure against your real portfolio. It is not an investment adviser.
Wondering how DHR or RVTY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Danaher Corporation
Ask Walnut's AI anything about DHR and see how it fits what you own.
FAQ
What is the difference between DHR and RVTY?
+
Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). Revvity runs two reporting segments of nearly identical size. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is DHR or RVTY the better stock?
+
Neither is universally better. DHR is the larger incumbent; RVTY is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, DHR or RVTY?
+
On forward P/E (as of November 2026), DHR trades at 23.98x and RVTY at 24.48x, so DHR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both DHR and RVTY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of DHR vs RVTY?
+
DHR: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 37x on GAAP earnings with a forward P/E near 24x as of November 20, 2026), leaving little room for disappointment. Core revenue growth has been slow, around 2% for 2025 and roughly flat in early 2026, so the thesis leans heavily on the bioprocessing recovery arriving on schedule. Biopharma and academic funding cycles, hospital and diagnostics testing volumes, and currency swings all move results. China demand and policy, along with broader biotech funding conditions, are additional swing factors. As a diversified conglomerate, weakness in any one segment can offset strength elsewhere. The shares gave back ground after the third-quarter beat, which shows that strong prints are already expected at this valuation. Total debt of about $27.8 billion against about $5.7 billion of cash is manageable for a company of this size but limits how large the next acquisition can be without more borrowing. RVTY: The most immediate risk is that a chunk of 2026 profit does not repeat. Following the Supreme Court's February 20, 2026 ruling that the International Emergency Economic Powers Act does not authorize tariffs, Revvity applied through the Customs and Border Protection refund process for $20.2 million and had received $16.2 million by July 5, 2026. The company books these on receipt and has recorded no refund receivable, and the full $16.2 million landed in cost of revenue in a single quarter, worth roughly $0.11 of the $1.41 adjusted EPS and a good part of the 260 basis points of gross margin expansion. Second, the end market has not fully turned. Pharma and biotech sales declined mid-single digits including software in the quarter, academic and government budgets remain unsettled, and instruments are a deferrable purchase when customers are cautious. Third, the China divestiture is signed but not closed, with completion expected only by the end of 2027 and conditioned on regulatory approval, so Revvity carries the unit's declining results in the meantime while guiding without it. Fourth, the balance sheet is intangible-heavy: ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles against ~$12.05 billion of total assets and ~$7.23 billion of equity, which leaves real impairment exposure if any acquired franchise underperforms. Fifth, restructuring is ongoing and disruptive, with severance actions in the first half of 2026 touching roughly 5% of the workforce and ~$46.2 million of charges recorded. Sixth, reproductive health revenue is tied to birth rates and to public-health screening budgets, both outside the company's control, and tuberculosis testing in the Americas is already a stated drag. Debt is ~$2.65 billion after the July repayment, with interest expense of ~$47.7 million in the half. Finally, after a roughly 48% gain in 2026 the stock trades near $145 and at about 24 times expected 2027 earnings, a premium to its own history that leaves little room for a guidance miss, and the shares already fell about 8.5% in the month to November 20 despite a third-quarter beat. Reported revenue growth was only about 4.3% in that quarter, so most of the earnings growth still has to come from margin and share count.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DHR or RVTY; figures are approximate and dated (as of November 2026). Verify current data before investing.